Search Results

You are looking at 91 - 100 of 295 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Single-Arm Longitudinal Study to Evaluate a Decision Aid for Women Offered Neoadjuvant Systemic Therapy for Operable Breast Cancer

Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle, and for the Australia and New Zealand Breast Cancer Trials Group

Killelea BK . Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States . Cancer 2015 ; 121 : 2544 – 2552 . 11. Shin HC Han W Moon HG . Breast-conserving surgery after tumor downstaging by

Full access

Bladder Cancer

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

involvement), similar to that for patients who undergo a radical cystectomy. Neoadjuvant Chemotherapy Increasing data support the role of neoadjuvant chemotherapy before cystectomy for T2 and T3 lesions. 40 – 42 Two randomized trials showed a survival

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

of neoadjuvant chemotherapy (FOLFIRINOX for 2 months) and chemoradiation followed by surgical resection and adjuvant gemcitabine. Early findings have been encouraging, Dr. Tempero indicated. A larger trial in borderline resectable disease will

Full access

Systemic Management of Colorectal Cancer

Wells A. Messersmith

Guidelines clearly distinguish between resectable/curative disease and unresectable disease. For patients with resectable tumors, “You can go straight to resection or consider neoadjuvant chemotherapy,” Dr. Messersmith said. For those with resectable

Full access

Value of Functional Imaging by PET in Esophageal Cancer

Thomas Schmidt, Florian Lordick, Ken Herrmann, and Katja Ott

posttherapeutic FDG-negative tumor is not synonymous with a pCR. Recently, the CROSS study group showed that pCR after neoadjuvant chemotherapy increases with time from completion of chemoradiotherapy. 41 So far no data are available on posttherapeutic evaluation

Full access

Modern Staging and Utility of PET Imaging in Esophageal Cancer Management

Kwang-Yu Chang, Jang-Yang Chang, Joseph Chao, and Yun Yen

. Urschel JD Vasan H Blewett CJ . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer . Am J Surg 2002 ; 183 : 274 – 279 . 24. Ancona E Ruol A

Full access

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Virginia G. Kaklamani and William J. Gradishar

study, the use of neoadjuvant chemotherapy is considered equivalent to adjuvant chemotherapy as far as long-term efficacy is concerned. Can Response to Preoperative Therapy Predict for Long-Term Outcomes? After 9 years of follow-up in the NSABP B

Full access

University of Michigan Comprehensive Cancer Center Opportunities for Improvement Project

Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver

UMCCC experienced more rapid transition from biopsy to surgery or neoadjuvant chemotherapy, and surgery to adjuvant chemotherapy than those who received a portion of their care outside the center. This finding is not surprising, because EHR and internal

Full access

Bone Cancer

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman, and Hema Sundar

functional outcomes. 185 In patients with high-grade osteosarcomas with good histologic response to neoadjuvant chemotherapy, limb-sparing surgery is considered the preferred surgical modality if wide surgical margins could be achieved. 182 , 186 Amputation

Full access

Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson

nonamplification by fluorescence in situ hybridization, and a Ki-67 level of 70%. Further staging using a PET/CT scan, bone scan, and brain MRI did not show definite evidence of distant metastatic disease. The patient received neoadjuvant chemotherapy with